1. Home
  2. EKSO vs LEXX Comparison

EKSO vs LEXX Comparison

Compare EKSO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ekso Bionics Holdings Inc.

EKSO

Ekso Bionics Holdings Inc.

HOLD

Current Price

$7.12

Market Cap

23.2M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.74

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EKSO
LEXX
Founded
2005
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.2M
18.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EKSO
LEXX
Price
$7.12
$0.74
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$9.50
$1.50
AVG Volume (30 Days)
5.9M
1.4M
Earning Date
03-02-2026
01-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,749,000.00
$522,000.00
Revenue This Year
N/A
$13.35
Revenue Next Year
$54.65
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.05
52 Week Low
$2.73
$0.46
52 Week High
$12.70
$2.03

Technical Indicators

Market Signals
Indicator
EKSO
LEXX
Relative Strength Index (RSI) 49.24 47.30
Support Level $7.70 $0.68
Resistance Level $9.11 $0.81
Average True Range (ATR) 1.09 0.07
MACD -0.17 0.02
Stochastic Oscillator 3.80 77.12

Price Performance

Historical Comparison
EKSO
LEXX

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: